These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23797718)

  • 1. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
    Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
    Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
    Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
    Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
    Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
    Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
    Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
    J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
    Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
    J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.
    Schofield L; Grieu F; Goldblatt J; Amanuel B; Iacopetta B
    Fam Cancer; 2012 Mar; 11(1):1-6. PubMed ID: 22120844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center.
    Heald B; Plesec T; Liu X; Pai R; Patil D; Moline J; Sharp RR; Burke CA; Kalady MF; Church J; Eng C
    J Clin Oncol; 2013 Apr; 31(10):1336-40. PubMed ID: 23401454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutation in sporadic colorectal cancer and Lynch syndrome.
    Thiel A; Heinonen M; Kantonen J; Gylling A; Lahtinen L; Korhonen M; Kytölä S; Mecklin JP; Orpana A; Peltomäki P; Ristimäki A
    Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.
    Colling R; Church DN; Carmichael J; Murphy L; East J; Risby P; Kerr R; Chetty R; Wang LM
    J Clin Pathol; 2015 Dec; 68(12):1036-9. PubMed ID: 26201544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancer.
    Jin HY; Liu X; Li VK; Ding Y; Yang B; Geng J; Lai R; Ding S; Ni M; Zhao R
    BMC Cancer; 2008 Feb; 8():44. PubMed ID: 18257912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N_LyST: a simple and rapid screening test for Lynch syndrome.
    Susanti S; Fadhil W; Ebili HO; Asiri A; Nestarenkaite A; Hadjimichael E; Ham-Karim HA; Field J; Stafford K; Matharoo-Ball B; Hassall JC; Sharif A; Oniscu A; Ilyas M
    J Clin Pathol; 2018 Aug; 71(8):713-720. PubMed ID: 29472252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
    Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
    Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.